Eiger Biopharmaceuticals Financials
EIGRDelisted Stock | USD 0.74 0.03 3.90% |
Eiger |
Understanding current and past Eiger Biopharmaceutica Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Eiger Biopharmaceutica's financial statements are interrelated, with each one affecting the others. For example, an increase in Eiger Biopharmaceutica's assets may result in an increase in income on the income statement.
Eiger Biopharmaceutica Stock Summary
Eiger Biopharmaceutica competes with Spero Therapeutics, Bolt Biotherapeutics, Coherus BioSciences, Cingulate, and Lyra Therapeutics. Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California. Eiger Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 51 people.Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US28249U1051 |
Business Address | 2155 Park Boulevard, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.eigerbio.com |
Phone | 650 272 6138 |
Currency | USD - US Dollar |
Eiger Biopharmaceutica Key Financial Ratios
Eiger Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Eiger Biopharmaceutica's current stock value. Our valuation model uses many indicators to compare Eiger Biopharmaceutica value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Eiger Biopharmaceutica competition to find correlations between indicators driving Eiger Biopharmaceutica's intrinsic value. More Info.Eiger Biopharmaceuticals is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Eiger Biopharmaceutica by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Eiger Biopharmaceutica Market Pulse
Quote | 0.74 |
Change(%) | 3.90 |
Change | 0.03 |
Open | 0.77 |
Low | 0.72 |
High | 0.78 |
Volume | 0 |
Exchange | NASDAQ |
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Eiger Biopharmaceutica is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Eiger has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Eiger Biopharmaceutica's financials are consistent with your investment objective using the following steps:- Review Eiger Biopharmaceutica's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Eiger Biopharmaceutica's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Eiger Biopharmaceutica's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Eiger Biopharmaceutica's stock is overvalued or undervalued.
Eiger Biopharmaceutica December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Eiger Biopharmaceutica help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Eiger Biopharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Eiger Biopharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Eiger Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Eiger Biopharmaceutica's daily price indicators and compare them against related drivers.
Information Ratio | (0.09) | |||
Maximum Drawdown | 36.25 | |||
Value At Risk | (8.97) | |||
Potential Upside | 8.89 |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in Eiger Stock
If you are still planning to invest in Eiger Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eiger Biopharmaceutica's history and understand the potential risks before investing.
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |